Treatment with PR-619 has been shown to lead to dephosphorylation of Tau and promote the association of Tau with microtubules, suggesting a potential role in controlling AD and other neurodegenerative diseases through Tau phosphorylation [156]. This evidence concerns the gene MAPT and Alzheimer disease.